One in every 7 men is diagnosed with prostate cancer, and approximately 27,500 deaths per year are attributed to this disease. Prostate cancer represents a broad spectrum of diseases ranging from the indolent to the highly aggressive but, in general, tends to be slower growing than most other solid cancers. The methods based on serum prostate- specific antigen (PSA) followed by random biopsies tend to overdiagnose small indolent tumors, which begin appearing in men at a young age at autopsy and are found throughout the prostates in men ages 50 years and older.This combination of PSA screening and random biopsy has yielded disappointing
clinical outcomes. Prostate MRI has seen increasing interest in recent years. Multiparametric MRI (mpMRI)
prostate allows accurate anatomical and functional imaging of the prostate gland and diagnosis of significant (intermediate and high risk) prostate cancer. mpMRI can also be utilised in active surveillance for patients with low- and intermediate-risk prostate cancer and guide targeted prostate biopsies.
The quality of the multiparametric sequences employed depends not only on the hardware and software utilised and scanning parameters selected, but also on
patient-related factors. The radiology community is continuously working on new MRI techniques and sequences to improve PCa diagnosis.
)